Organization
Department of Genitourinary Oncology
5 abstracts
Abstract
Temozolomide plus cisplatin versus toripalimab (anti-PD-1) as adjuvant therapy in resected mucosal melanoma.Org: Key Laboratory of Carcinogenesis and Translational Research, Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Department of Melanoma and Sarcoma,
Abstract
Camrelizumab plus apatinib and temozolomide as first-line therapy for advanced acral melanoma: 2-year survival results from CAP 03.Org: Department of Melanoma and Sarcoma Oncology, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute (Beijing Cancer Hospital), Beijing, China, Melanoma Institute Australia, Department of Genitourinary Oncology,
Abstract
Tucidinostat plus toripalimab in patients with unresectable or metastatic melanoma: An open-label, single-arm phase II study.Org: Department of Melanoma and Sarcoma Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China, Department of Genitourinary Oncology, Melanoma Institute Australia, Sydney, Australia,
Abstract
Analysis of overall survival (OS) and progression-free survival (PFS) in the phase 1b clinical trial of anti–PD-1 ab (toripalimab) plus intrahepatic injection of OrienX010 in stage IV melanoma with liver metastases.Org: Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma Oncology, Peking University Cancer Hospital & Institute, Department of Renal Cancer and Melanoma, Department of Ultrasound, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China,
Abstract
Identifying the driver histology responsible for the inferior clinicopathologic features associated with plasmacytoid bladder cancer.Org: H. Lee Moffitt Cancer Center and Research Institute, Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center & Research Institute,